LONDON (Alliance News) - Mid Wynd International Investment Trust PLC Tuesday said it has outperformed its benchmark index in the first quarter of the financial year.
Mid Wynd, which has stakes in a range of equities, including IP Group PLC and ASOS PLC, said its net asset value total return was 7.0% in the three months to September 30, compared to a 1.3% total return from the FTSE World Index in sterling terms.
Its NAV per share was 268.6 pence on September 30, up from 253.1 pence on June 30.
Mid Wynd shares Tuesday closed at 261.98 pence, down 258.00 pence, or 2.1%.
By Samuel Agini; samagini@alliancenews.com; @samuelagini
Copyright 2013 Alliance News Limited. All Rights Reserved.


(Alliance News) - IP Group PLC on Tuesday confirmed that it recently received an acquisition proposal from Railways Pension Trustee Co Ltd through its...


(Sharecast News) - IP Group confirmed on Tuesday that it has rejected a takeover proposal from shareholder Railways Pension Trustee Company, or Railpe...


(Alliance News) - The FTSE 100 rose on Monday, and the pound made headway, as UK Prime Minister Keir Starmer confirmed he was stepping down and as tal...


(Alliance News) - IP Group PLC on Tuesday confirmed that it recently received an acquisition proposal from Railways Pension Trustee Co Ltd through its...


(Sharecast News) - IP Group confirmed on Tuesday that it has rejected a takeover proposal from shareholder Railways Pension Trustee Company, or Railpe...


(Alliance News) - The FTSE 100 rose on Monday, and the pound made headway, as UK Prime Minister Keir Starmer confirmed he was stepping down and as tal...


(Sharecast News) - Railways Pension Trustee Company (Railpen) said on Monday that IP Group has rejected a takeover proposal of up to 74.7p per share.


(Alliance News) - Railways Pension Trustee Company Ltd, or Railpen, on Monday said IP Group PLC has rejected its possible takeover offer worth GBP615....


(Alliance News) - IP Group PLC on Tuesday announced that portfolio company Istesso has commenced dosing for the IST-03 trial of leramistat in sarcopen...


(Sharecast News) - Science and technology investment firm IP Group said on Tuesday that portfolio company Istesso has begun dosing patients in a Phase...